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Abstract
Background: Point of care testing (PoCT) may be a useful adjunct in the management of chronic
conditions in general practice (GP). The provision of pathology test results at the time of the
consultation could lead to enhanced clinical management, better health outcomes, greater
convenience and satisfaction for patients and general practitioners (GPs), and savings in costs and
time. It could also result in inappropriate testing, increased consultations and poor health outcomes
resulting from inaccurate results. Currently there are very few randomised controlled trials (RCTs)
in GP that have investigated these aspects of PoCT.
Design/Methods: The Point of Care Testing in General Practice Trial (PoCT Trial) was an
Australian Government funded multi-centre, cluster randomised controlled trial to determine the
safety, clinical effectiveness, cost effectiveness and satisfaction of PoCT in a GP setting.
The PoCT Trial covered an 18 month period with the intervention consisting of the use of PoCT
for seven tests used in the management of patients with diabetes, hyperlipidaemia and patients on
anticoagulant therapy. The primary outcome measure was the proportion of patients within target
range, a measure of therapeutic control. In addition, the PoCT Trial investigated the safety of
PoCT, impact of PoCT on patient compliance to medication, stakeholder satisfaction, cost
effectiveness of PoCT versus laboratory testing, and influence of geographic location.
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Discussion: The paper provides an overview of the Trial Design, the rationale for the research
methodology chosen and how the Trial was implemented in a GP environment. The evaluation
protocol and data collection processes took into account the large number of patients, the broad
range of practice types distributed over a large geographic area, and the inclusion of pathology test
results from multiple pathology laboratories.
The evaluation protocol developed reflects the complexity of the Trial setting, the Trial Design and
the approach taken within the funding provided. The PoCT Trial is regarded as a pragmatic RCT,
evaluating the effectiveness of implementing PoCT in GP and every effort was made to ensure that,
in these circumstances, internal and external validity was maintained.
Trial Registration: 12612605000272695
Background
Point of care testing (PoCT) has been used for many years
and is increasingly being utilised in the Australian general
practice (GP) setting. PoCT is defined as any test that is
performed at the time at which the test result enables a
clinical decision to be made and an action taken that leads
to an improved health outcome [1]. PoCT has the poten-
tial to provide better monitoring of chronic conditions,
improved therapeutic control, more rational prescribing,
better clinical decisions within the consultation time-
frame, greater patient compliance with pathology
requests, and fewer visits to the doctor [2-4].
The literature suggests that there is a lack of evidence for
several of these benefits, particularly those relating to clin-
ical outcomes. Reduction in referrals, and earlier and
more rationalised treatment has been reported in a study
involving PoCT [5] but changes in prescribing patterns
have not occurred. Some evidence is available on the role
of PoCT in improving glycaemic control [2,6], cholesterol
and lipid levels [7], and oral anticoagulant control [8],
although not for microalbuminuria.
A primary concern relating to PoCT is quality manage-
ment. For PoCT to be introduced into the GP environ-
ment, it is important that it is proven to be accurate and
reliable [9]. This requires those practices undertaking such
testing to meet both internal quality control (QC) and
external quality assurance (QA) standards. Hobbs [10]
suggests a model for PoCT in primary care that incorpo-
rates laboratory training for GP staff with external QA
from a central laboratory. A necessary part of quality man-
agement is the adequate training of staff operating the
PoCT devices and this includes the requirement for an
understanding of QC and QA processes [11,12].
PoCT in GP will only be effective if the results obtained
from the testing devices are comparable with laboratory
results [1,13]. A number of studies have shown that PoCT
using a variety of portable monitoring devices can pro-
duce test results similar to laboratory results for a number
of specific tests including HbA1c [2,14], anticoagulation
monitoring [15-19], microalbuminuria and cholesterol
[20]. Variability between laboratories and primary care
sites, however, demonstrates the need for participation in
QA programs [1].
While a large number of studies have been undertaken on
the use of PoCT in the primary care setting, few studies
have undertaken an economic analysis of PoCT [5].
Hobbs et al's [3] systematic review of PoCT in primary
care could not draw any conclusions regarding cost effec-
tiveness of PoCT because of insufficient research data.
Some studies indicate that PoCT is more expensive when
compared to laboratory testing [2,21], but this may be off-
set by long term societal gains such as prolonged life or
reduced hospital stays [5]. It should, however, be noted
that the cost effectiveness of PoCT appears likely to vary
according to the disease group and the test in question [2].
The attitudes of key stakeholders and their satisfaction
with PoCT form an important part of the assessment of
introducing PoCT into GP. These stakeholders include
patients, GPs, practice staff and pathology laboratories.
PoCT may lead to greater convenience for GPs and
patients but result in greater costs and require organisa-
tional changes that may reduce stakeholder satisfaction.
There is conflicting research in this area. Hilton et al's [22]
study on general practitioner and practice nurse attitudes
to PoCT concluded that GPs did not find PoCT a useful
addition to their practice, while nurses reported that pres-
sure on their time was a limitation for PoCT. Grieve et al.
[2] found no difference in patient satisfaction between
diabetes clinics using PoCT or usual laboratory testing,
however, patients did record a higher level of satisfaction
with test information if they had PoCT rather than con-
ventional testing. An Australian study investigating the
attitudes of patients and GPs to PoCT found that GPs and
patients supported PoCT because of its convenience, qual-
ity, role in patient care and efficiency. However, registra-
tion costs and QA fees were cited as areas of dissatisfaction
by GPs [23].Trials 2008, 9:50 http://www.trialsjournal.com/content/9/1/50
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While a number of studies have been undertaken on the
cost effectiveness, clinical effectiveness, safety or satisfac-
tion with PoCT, there have been no randomised control-
led trials (RCTs) that evaluate all these outcomes in the
GP setting. The PoCT Trial was implemented to address
this gap.
Methods
Overview of design
The PoCT Trial is a cluster randomised controlled trial to
evaluate the intervention of PoCT on the management of
patients with either diabetes, hyperlipidaemia or on anti-
coagulant therapy. A clustered design was chosen to avoid
treatment group contamination and for administrative
convenience. The Trial commenced in September 2005
and continued for 18 months across 58 general practices
based in urban, rural and remote locations across three
states in Australia.
The Trial Design was developed in partnership with the
PoCT Steering Group, a working group of the Quality Use
of Pathology Committee PoCT Implementation Subcom-
mittee of the Australian Government [24]. The original
Trial Design was then modified by the Trial Evaluators
(CL, AG, PR, LY, KW) and the evaluation protocol and sta-
tistical analysis plan developed for the adapted Trial
Design.
The PoCT Trial involved collaboration between three
organisations who administered different aspects of the
Trial. Trial Management and Evaluation was undertaken
by the Disciplines of General Practice and Public Health
at the University of Adelaide. The provision of devices,
device operator training and QC was undertaken by the
Community Point-of-Care Services Unit, Flinders Univer-
sity Rural Clinical School (Device Group) and the external
QA program was provided by the RCPA Quality Assurance
Program Pty Ltd (QAP).
The primary research question of the Trial was:
Should PoCT in GP be implemented by the Australian
Government?
The Trial evaluated seven key questions:
1. Is it safe to perform PoCT in a GP setting?
2. Is the clinical effectiveness of PoCT the same or better
than the same tests using pathology laboratory testing?
3. Is it the same or more cost effective to perform PoCT
compared with pathology laboratory testing?
4. Are patients and other stakeholders more satisfied with
PoCT than with pathology laboratory testing?
5. Are there differences between urban, rural and remote
geographic regions in the treatment effects being meas-
ured?
6. Would the regulatory environment used for the Trial
meet the needs of all the stakeholders if PoCT were to be
made more generally available?
7. What would the appropriate MBS fees be for the PoC
tests selected in the Trial?
This paper focuses on the evaluation protocol and meth-
ods developed to investigate the first five research ques-
tions.
A number of hypotheses were developed in order to
answer each of these questions and are shown in Table 1.
The PoCT Trial had two phases, Phase I lasting six months
and Phase II lasting twelve months. In Phase I, patients in
practices in the intervention group had pathology testing
performed both by the pathology laboratory in the usual
manner and by PoCT in the practice. The control group
undertook testing by the pathology laboratory.
In Phase II, intervention group patients were tested using
only PoCT at the practice, although pathology laboratory
testing could be performed at any time at the request of
the general practitioner, while control group patients con-
tinued to be tested by the pathology laboratory as usual.
Study setting
The Australian Medicare Program aims to provide equita-
ble access to medical and hospital services for all Austral-
ian residents. The Department of Health and Ageing (the
Department) has policy responsibility for Medicare, with
Medicare Australia being responsible for Medicare admin-
istration and the payment of Medicare benefits, which are
detailed in the Medicare Benefits Schedule (MBS). The
Medical Services Advisory Committee (MSAC) advises the
Department on the strength of evidence relating to the
safety, clinical effectiveness and cost effectiveness of new
and emerging medical services and technologies, and
under what circumstances listing on the MBS should be
supported.
To enable the payment of Medicare benefits for pathology
services, pathology testing must be undertaken by a
pathology laboratory that is accredited to provide a partic-
ular service. Pathology collection centres must be
approved to enable the payment of Medicare benefits for
services performed on specimens collected. Patients canTrials 2008, 9:50 http://www.trialsjournal.com/content/9/1/50
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Table 1: Key research questions and associated hypotheses
Area of key
 research question
Hypotheses developed Level of analysis
Safety All designated staff in the PoCT practices meet the required competency 
level to perform PoCT
Practice staff level
All PoCT practices obtain QC results within the acceptable performance 
range
Practice level
In terms of accuracy, all PoCT practice results meet the required QA 
performance levels for the pathology laboratories
Practice level
In terms of precision, PoCT practice results meet the required QA 
performance levels for the pathology laboratories
Practice level
Results obtained from PoCT devices for each patient closely agree with 
results obtained for the same patient from pathology laboratory testing
Test level
All intervention practices meet the standards for PoCT in GP and obtain 
accreditation
Practice level
The number of serious adverse events reported in PoCT patients per 
person-year is the same as or fewer than the number of serious adverse 
events reported in control patients per person-year
Patient level
The proportion of PoCT patients who experience one or more serious 
adverse events is the same as or less than the proportion of control 
patients who experience one or more serious adverse events
Patient level
Clinical effectiveness The proportion of PoCT patients who have pathology results within the 
target range is the same as or greater than the proportion of control 
patients who have pathology results within the target range
Patient level
The proportion of total tests within the target range in PoCT practices is 
the same as or greater than the proportion of total tests within the 
target range in control practices
Test (within patient) level
The number of general practitioner visits for PoCT patients per person-
year is different than the number of general practitioner visits for control 
patients per person-year
Patient level
PoCT patients report the same or greater improvement in compliance 
with disease management as directed by medical staff as control patients
Time of questionnaire administration (within 
patient) level
Satisfaction The average change in attitudes in GPs from PoCT practices is different 
to the average change in attitudes in GPs from control practices
Time of questionnaire administration (within 
GP) level
The average change in attitudes in patients from PoCT practices is 
different to the average change in attitudes in patients from control 
practices
Time of questionnaire administration (within 
patient) level
Device operators report a change in average attitudes Time of questionnaire administration (within 
device operator) level
Pathology providers report a change in average attitudes Time of questionnaire administration (within 
pathology provider) level
The average level of satisfaction with regard to PoCT assisting with 
disease management in intervention GPs is different to the average level 
of satisfaction with disease management in control GPs
GP level
The average level of satisfaction with regard to work flow in intervention 
GPs is different to the average level of satisfaction with regard to work 
flow in control GPs
GP level
The average level of satisfaction with testing in intervention GPs is 
different to the average level of satisfaction with testing in control GPs
GP level
The average level of satisfaction with regard to the collection process in 
intervention patients is different to the average level of satisfaction with 
regard to the collection process in control patients
Patient level
The average level of confidence in the process in intervention patients is 
different to the average level of confidence in the process in control 
patients
Patient level
The average level of confidence in the results in intervention patients is 
different to the average level of confidence in the results in control 
patients
Patient level
The average level of satisfaction with regard to transport in intervention 
patients is different to the average level of satisfaction with regard to 
transport in control patients
Patient levelTrials 2008, 9:50 http://www.trialsjournal.com/content/9/1/50
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either attend an approved collection centre or can have
their blood, urine or other samples taken by or on behalf
of the general practitioner referring them for the service.
The specimen is then delivered to the pathology labora-
tory for testing. For patients in rural and remote locations,
transportation time is critical and turnaround time for
results can be longer than in urban settings, with a possi-
ble impact on patient management.
Currently in Australia only a small number of point of
care tests, such as pregnancy tests, are funded through the
MBS for GP. To claim a broader range of pathology tests a
practice must be a Category M (GP) Accredited Pathology
Laboratory. This requires that they participate, at a cost, in
the inspection and accreditation process implemented by
the National Association of Testing Authorities. It has
been suggested that the costs associated with accreditation
and annual registration currently make it prohibitive for
GP to participate, resulting in very few such practices exist-
ing in Australia [23]. The outcomes of the PoCT Trial will
be used by the Department and its relevant advisory bod-
ies (including MSAC) to determine whether an expanded
range of PoCT for GP should be recommended for inclu-
sion in the MBS.
Participants
The Trial aimed to recruit 60 practices across three geo-
graphic locations (urban, rural and remote) in South Aus-
tralia, New South Wales and Victoria. Node support
officers (NSOs) were employed across the three geo-
graphic regions with the aim of recruiting 20 practices
each. Divisions of GP were engaged to assist in the recruit-
ment process. Once a general practitioner or practice had
expressed an interest in being involved in the Trial, further
information was sought in the form of a practice checklist.
Those who met the eligibility criteria and signed on to par-
ticipate were included in the randomisation.
All practices were required to recruit a minimum of 30
patients on anticoagulant therapy, 35 with diabetes and
50 with hyperlipidaemia. Patients were initially recruited
in the first three months of the Trial. Patients needed to
have established and stabilised diabetes, and/or hyperlip-
idaemia, and/or be taking anticoagulant medicine such as
warfarin. The inclusion and exclusion criteria for practices
and patients are provided in Table 2. Practices were pro-
vided with assistance to undertake database searches to
identify eligible patients and a software program to ran-
domly select eligible patients to be invited to participate
in the Trial. These patients were sent, by the practice, a let-
The average level of satisfaction with regard to loss of work time in 
intervention patients is different to the average level of satisfaction with 
regard to loss of work time in control patients
Patient level
The average level of satisfaction with regard to disease compliance in 
intervention patients is different to the average level of satisfaction with 
regard to disease compliance
Patient level
Device operators are satisfied with PoCT Device Operator level
Pathology providers are satisfied with PoCT Pathology Provider level
Cost effectiveness The value of the resources used in PoCT is different from that of those 
used in pathology laboratory testing
Patient level
Table 1: Key research questions and associated hypotheses (Continued)
Table 2: Inclusion and Exclusion criteria for practices and patients in the PoCT Trial
Participant
 Group
Inclusion criteria Exclusion criteria
Practices Accredited through RACGP Standards for GP
Minimum patient load from all disease groups:
20 tests per month INR
10 test per month Lipids
5 tests per month HbA1c
Suitable facilities for PoCT – premises, staff and medical record system
Involved in other primary care pathology trial
Patients Diabetes Fasting plasma glucose ≥ 7.0 mmol/L or
2 hour post glucose load ≥ 11.1 mmol/L
< 18 years
Condition not stabilised
Unable to understand written instructions in 
English
Hyperlipideamia Eligible for PBS lipid lowering drugs Significant cognitive impairment
Anticoagulant
therapy
Prescribed Warfarin
INR test result within the therapeutic range for at least 
one month (ie stabilised)
Poor insight into their disease process or 
physical disabilitiesTrials 2008, 9:50 http://www.trialsjournal.com/content/9/1/50
Page 6 of 14
(page number not for citation purposes)
ter of invitation, an information sheet and a consent form.
Once patients had consented, they were provided with an
identification card with their ID number and those in the
intervention group began PoCT.
All GPs from each practice involved in the Trial were
invited to participate. Those interested in participating
were required to sign a consent form, to sign a letter of
agreement which outlined the terms and conditions of
their participation in the Trial and were asked to provide
proof of their current Medical Malpractice Insurance.
Participating practices were required to provide contact
details for all associated pathology providers. The Trial
Management team encouraged these pathology providers
to participate in the Trial and developed appropriate links
for data transfer where possible to reduce the burden on
practices.
Practices randomised to the intervention group were
required to nominate at least one staff member, preferably
a practice nurse, to undertake training in use of the PoCT
devices and the Trial protocol.
Randomisation and allocation
Practices were randomly allocated to the intervention or
control arm in the ratio 1:1. Randomisation was stratified
by geographic area (urban, rural and remote) and used
randomly permuted blocks of size 2, 4 and 6. The random
allocation sequence was generated using ralloc.ado ver-
sion 3.2.5 in Stata 9.0.
Practice allocation to treatment group was performed by
central randomisation by phone/email after consent was
obtained. The recruiters did not know the random alloca-
tion sequence. Once randomisation had been under-
taken, all the patients recruited for the practice were then
deemed intervention or control depending on which arm
of the Trial each practice was allocated.
Due to the type of intervention, neither participants nor
project staff were blinded to the treatment allocation.
Intervention
Patients recruited in the intervention group had their
pathology testing for either HbA1c, microalbumin, lipids
(total cholesterol, triglyceride and high density lipopro-
tein cholesterol (HDL-C)) or INR using PoCT devices by
their practice for 18 months. Patients in the control prac-
tices had these same tests undertaken using their usual
care – the pathology laboratory.
The practices in the intervention group were provided
with three PoCT devices – DCA 2000, CoaguChek S and
Cholestech LDX. The selection of devices was based on
non-analytical and analytical criteria prior to the com-
mencement of the PoCT Trial. Group training sessions
were held over two days for the practice staff who would
use the devices (known as device operators) and follow-
up sessions were provided 12 months later. Training
incorporated an introduction to PoCT, quality manage-
ment, accuracy and precision of results and training in the
use of each device. At the end of their training, their com-
petency was assessed by the Device Group.
Quality Management
The practices were required to perform internal QC and
QA testing designed for the PoCT Trial practices. The prac-
tices also participated in an accreditation process. The
accreditation process and training was based on the
Interim Standards for Point of Care Testing in General
Practice: Incorporating the Trial Guidelines developed by
the Australian Government [25].
Data collection and outcome measures
Data were collected at various points throughout the
PoCT Trial to answer the five key research questions (see
Additional file 1). In determining the data collection tools
and outcome measures, it was necessary to ensure that
these were applicable across the three different clinical
conditions and could accommodate patients with more
than one of the three conditions. Thus, validated tools or
measures appropriate to only one condition could not be
used. The Evaluation Team developed unique data collec-
tion tools and also utilised validated tools where applica-
ble, and these are described below.
Safety
To determine the safety of PoCT, a number of measures
were identified. These included: performance in quality
management; performance testing; compliance with
standards for PoCT; and serious adverse events (SAEs)
reporting.
Internal QC for the intervention practices was assessed
using QC materials comprising two levels of HbA1c,
microalbumin and lipids and one level for INR. Device
operators forwarded their results to the Device Group for
analysis. This was initially undertaken fortnightly and
after three months undertaken monthly for the remainder
of the Trial. Practices received a feedback report every
three months reporting their precision expressed as a coef-
ficient of variation.
The QAP provided an external assessment of the PoCT
device performance and a comparison with all practices in
the Trial. Intervention practices were provided with an
external QA kit for each test every six months during the
Trial. The kit contained samples which needed to be tested
every fortnight by the device operators. Practices for-Trials 2008, 9:50 http://www.trialsjournal.com/content/9/1/50
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warded results by mail or via the QAP website to QAP Pty
Ltd and acceptable limits of good performance were deter-
mined. At the end of each testing cycle, practices were pro-
vided with a summary of their performance (precision
and accuracy) over the previous six months and a compar-
ison with other participating sites.
The number and types of SAEs were recorded throughout
the length of the PoCT Trial. Events occurring up to one
month after completion of Phase II were also recorded for
patients on anticoagulant therapy. The number of SAEs
reported in patients per person-year was calculated, as
well as the proportion of patients experiencing one or
more SAEs.
Clinical effectiveness
To determine the clinical effectiveness of PoCT compared
with pathology laboratory testing, the PoCT Trial focused
on therapeutic control and impact on patient care.
To measure therapeutic control, two outcomes were con-
sidered: firstly, the proportion of patients within target
range (prevalence) and secondly the proportion of tests
within target range for each type of test. The former was
the primary outcome measure for the Trial. The target
ranges used for the seven tests were based on clinical
guidelines and are defined in Table 3. For intervention
practices, patient test results were recorded on a specifi-
cally designed request/result form, with copies forwarded
to the Trial Manager every month. For control practices,
test results were collected from the pathology laboratory
through either hard copy or weekly electronic downloads
of results for those patients identified as participating in
the Trial. This was achieved with a PoCT Trial identifica-
tion sticker adhered to the pathology laboratory test
request form.
To measure the impact of PoCT on patient care, a number
of outcome measures were determined. These included:
number of general practitioner visits per person-year;
patient compliance with disease management; pharma-
ceutical prescribing; and process of care actions under-
taken by the general practitioner following a pathology
test.
General practitioner visits per person-year
Pathology results provided by PoCT at the time of a con-
sultation provide GPs with an opportunity to discuss the
test results with their patients immediately and imple-
ment any changes to improve the management of their
condition. Measuring the number of general practitioner
visits per person-year for patients in the PoCT Trial will
determine if PoCT leads to more or fewer visits. Some
research indicates that PoCT results in increased testing
[26], while others have found no significant difference
[27,28].
Medication compliance
It has been widely reported in the literature that non-com-
pliance to medication is substantial with an estimated 30–
40% of patients failing to take medications as prescribed
[29]. It is well known that low compliance to medication
compromises the effectiveness of treatment at substantial
costs to the patient (to the potential detriment of health),
to the health professional (treating morbidity) and to
society (economic impact) making it an important area to
improve [30-32]. To assess medication compliance a self-
administered questionnaire was sent to all patients twice
during the Trial.
Medication compliance was measured using the Medica-
tion Adherence Reporting Scale (MARS-5). The MARS-5 is
a five-item scale asking participants to indicate the fre-
quency with which they engage in each of five compo-
nents of non-compliant behaviour e.g. altering the dose or
forgetting to take a dose. Since 1996, the MARS-5 has been
used in studies across a variety of illnesses and in several
countries [33-36] The MARS-5 has been found to have
good reliability and validity [37].
Patients were also asked to comment about their beliefs
and attitudes towards medicines in general and medicines
prescribed for their condition. Past research has shown
that levels of medication compliance are associated with
patient beliefs about the necessity of taking medication
[37].
Process of care and prescribing patterns
In order to assess the impact of PoCT on general practi-
tioner management of the patient, the PoCT Trial meas-
ured the processes of care associated with each pathology
test. The availability of a test result during the consulta-
tion should assist the general practitioner to treat and
manage patients with the three conditions of interest [38].
Table 3: Target ranges by condition and test
Condition Test Target range
Diabetes [39,40] HbA1c < = 7%
Microalbuminuria [40] ACR < 3.6 female
< 2.6 male
Urine albumin > 20 μg/min
Hyperlipidaemia [42] Total cholesterol < 4.0 mmol/L
Triglycerides < 2.0 mmol
HDL-C > 1.0 mmol/L
INR [41] Atrial fibrillation and other 
conditions
2.0–3.0
Prosthetic heart valve 2.5–3.5Trials 2008, 9:50 http://www.trialsjournal.com/content/9/1/50
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Grieve et al [2] found that the provision of immediate test
results for HbA1c led to significantly more management
changes being made. The minimum number of processes
of care for the Trial were based on the clinical guidelines
developed for diabetes management, management of
patients on anticoagulant therapy and lipids management
[39-42] and depended on whether the test result was
within or outside the target range. The data were collected
through a case note audit (CNA) of a random sample of
patient medical records. A total of 18 practices, stratified
by treatment group and geographic location, were
included in the sample. Sixty-five patients were then ran-
domly selected from each of the chosen practices, or all
patients were selected if the practice had less than 65
patients participating in the Trial. Following training, the
auditors recorded the number and type of actions relating
to each pathology test performed during the Trial. Actions
included review of the test result by the general practi-
tioner, medication review, medication changes, lifestyle
advice given, referrals, blood pressure readings and
requests for follow-up testing.
PoCT has the potential to improve patient compliance
with medication and result in more appropriate and
timely prescribing by GPs [4]. To assess the influence of
PoCT on prescribing patterns, the data from the CNA were
used to identify changes made to prescribed medication
for each visit relating to a pathology test. These changes
include dosage changes, ceasing of medication and
change in type of drug. Prescribing patterns were analysed
separately for test results within and outside the target
range.
Cost effectiveness
To determine the cost effectiveness of PoCT versus pathol-
ogy laboratory testing, comparative cost analysis and cost
effectiveness analysis were undertaken, taking a societal
perspective. Costs included in the analysis were establish-
ment costs (equipment and training), consumable and
maintenance costs, QC and QA costs, accreditation costs,
costs associated with the practice consultation, testing
costs, patient costs and downstream costs.
Cost data were collected from a number of sources. These
included: MBS service claims (from Medicare Australia)
by participating GPs; general practitioner and device oper-
ator time through a time and motion study; patient borne
costs collected as part of the baseline and satisfaction
questionnaires; industry sources for costs related to PoCT
devices, allied health and specialist services from the
Medicare Australia database; and hospitalisations from
the CNA.
Cost effectiveness was measured using the incremental
cost effectiveness ratio. The intermediate outcome indica-
tor for each type of test was the proportion of patients
who are maintained within the normal clinical range for
that blood level based on the last test result collected dur-
ing the Trial (adequate control).
Satisfaction
The PoCT Trial assessed the satisfaction of patients, GPs,
device operators and pathology providers with PoCT, and
compared this with patient, GPs and pathology provider
satisfaction with usual pathology testing.
Attitudinal questions were administered at baseline (base-
line questionnaires) and at the end of the Trial (satisfac-
tion questionnaires) to patients, GPs, device operators
and pathology providers. Questions covered areas such as
preference, convenience, collection of blood, impact on
management of conditions, impact of PoCT on the prac-
tice and difficulty in the use of PoCT devices.
Additional data relating to satisfaction were also collected
through the satisfaction questionnaires. For the interven-
tion group these covered the areas of comparative quality
of the process (confidence in the collection process, con-
fidence in the results and comparative convenience (trans-
port, loss of work time and out of pocket expenses). The
control group were asked to rate their satisfaction in the
same areas as the intervention group, but as it related to
pathology laboratories.
For GPs and device operators, the satisfaction question-
naire focused on their preference, attitude and stated
behaviour around pathology testing. Those in the inter-
vention group had a number of additional questions
relating specifically to PoCT. Topics covered in the general
practitioner and device operator questionnaires included:
training; self assessed competence; accreditation method;
equipment; suitability of PoCT within the consultation;
perceived impact on patient health outcomes; conven-
ience and efficiency to the practice; and payment and
impact on interaction with pathology providers. Pathol-
ogy provider attitudes to PoCT were also obtained, cover-
ing areas such as analytical quality, accreditation,
laboratory involvement and impact on laboratory testing.
For all the satisfaction questionnaires, questions were
either designed specifically for the Trial or were taken
from other studies [2,15,22,23,43,44].
Influence of geographic location
The PoCT Trial sought to determine if there were differ-
ences between urban, rural and remote geographic
regions in the areas of safety, clinical effectiveness and
stakeholder satisfaction.Trials 2008, 9:50 http://www.trialsjournal.com/content/9/1/50
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Data management and safety monitoring
The Data Management and Analysis Centre (DMAC) of
the Discipline of Public Health at the University of
Adelaide was contracted to design and implement the IT
systems for the PoCT Trial. This system was comprised of
a Management Information System (MIS) and a data
entry system. The MIS was web-based and enabled the col-
lection and dissemination of Trial Management informa-
tion. The database into which management information
was collected could also be accessed by Trial Management
and Evaluation staff to produce reports as required. Access
to the Trial IT systems required logins and passwords and
all staff received training in its use. Data entry was per-
formed by specialised data entry staff in DMAC following
PoCT Trial standard operating procedures.
While the PoCT Trial was deemed low-risk, a Safety Sub-
committee was established to monitor SAEs and incidents
throughout its length, and to develop stopping rules. Prac-
tices, using a SAE Reporting Form, were required to report
any SAEs for recruited patients. The SAEs were categorised
as death, life threatening, permanent or significant disa-
bility or incapacity, hospitalisation, newly diagnosed can-
cer or other important medical event. Each SAE was
initially assessed by the Trial Manager to determine the
likelihood of the event resulting from involvement in the
PoCT Trial before being submitted to the Safety Subcom-
mittee for final assessment. In addition, any Trial related
incident was also required to be reported to the Trial Man-
ager for assessment using an Incident Reporting Form.
Incidents could be patient, device operator, device or QC/
QA related.
Throughout the PoCT Trial, all participants had access to
the three organisations administering the Trial via a free-
call telephone number.
Analysis plan
Statistical analysis
Non-inferiority tests were planned for hypotheses relating
to safety and clinical effectiveness. Comparative tests were
used for hypotheses relating to cost effectiveness and sat-
isfaction. Analyses were performed on an intention to
treat basis and took into account clustering at the practice
level, as well as the patient/general practitioner/device
operator level where appropriate, using mixed effects
models or generalised estimating equations. The level of
analysis varied depending on the hypothesis (see Table 1).
No adjustment was made for multiple tests of hypotheses
specified a priori.
A number of potential confounders were identified a pri-
ori as important. Both unadjusted and adjusted analyses
were performed. Conclusions were based on the results of
the adjusted analyses.
For outcomes relating to patients or repeated measures on
patients, adjustment was planned for the age and gender
of the patient. For outcomes to be analysed separately for
each type of test, the potential confounders to adjust for
(in addition to age and gender) depended on the type of
test. For tests relating to diabetes (HbA1c and microalbu-
min), adjustment was planned for time since diagnosis of
diabetes, Aboriginal or Torres Strait Islander (ATSI), use of
dietary control, prescription tablets and insulin for treat-
ing diabetes, and Body Mass Index (BMI). For HbA1c,
adjustment was also planned for baseline HbA1c result.
For lipids tests (total cholesterol, HDL-C and triglycer-
ides), adjustment was planned for known heart disease,
diabetes, ATSI, socio-economic status, smoking status and
baseline test result. For INR, adjustment was planned for
BMI, multiple co-morbidities and baseline INR result.
Analyses were adjusted for all planned confounders with
the exception of ATSI, due to the small number of such
patients in the Trial.
The form and extent of the missing data on both out-
comes and potential confounders was considered sepa-
rately for each analysis. Where there was evidence to
suggest the missing data were not missing completely at
random, 10 completed data sets were generated for analy-
sis using multiple imputation [45].
Sample size calculations
The primary outcome on which the sample size was based
was the proportion of patients with test results within tar-
get range, a measure of clinical effectiveness. It was con-
sidered that PoCT would be non-inferior to pathology
laboratory testing if the true difference in the proportion
of patients with test results within target range (interven-
tion minus control) was no less than -0.07. This non-infe-
riority margin was chosen as a compromise between
clinical significance and the feasibility of recruitment.
Sample size calculations were performed separately for
each type of test. Where multiple tests are performed for
the same condition (e.g. HbA1c and microalbumin tests
are both performed for patients with diabetes), the largest
of the estimated sample sizes was used.
Based on information obtained from a pathology labora-
tory, the proportion of control patients with pathology
results within the target range was assumed to be 0.12,
0.81, 0.77 and 0.53 for total cholesterol, HDL-C, triglycer-
ides and HbA1c respectively. Since no suitable informa-
tion was available for INR or microalbuminuria, the
proportion of control patients with pathology results
within the target range was assumed to be 0.5 for each of
these tests to give the largest sample size. The difference in
the proportion of patients with test results within target
range was assumed to be zero.Trials 2008, 9:50 http://www.trialsjournal.com/content/9/1/50
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A design effect of 2 was suggested in the original Trial
Design to allow for correlation between observations aris-
ing from the same cluster. The Trial Evaluators investi-
gated design effects in the Second Australian National
Blood Pressure Study (ANBP2) [46] which suggested that
a design effect of 2 may be conservative for a study con-
ducted in GP. Intra-cluster correlations for the PoCT Trial
will be published in a subsequent paper to assist in sam-
ple size calculations for future studies in a GP setting.
Using a one-sided, normal-approximation, non-inferior-
ity test of two proportions, a type 1 error probability of
0.05, 80% power and assuming a design effect of 2, the
number of patients required per group was 1262, 894 and
1262 for anticoagulant therapy, hyperlipidaemia and dia-
betes respectively.
Ethical approval and registration
The PoCT Trial was approved by five relevant independent
Australian Human Research Ethics Committees. The Trial
is registered with the Australian Clinical Trial Registry,
Number 12612605000272695 [47].
Results
Recruitment
Sixty-six practices expressed an interest in being involved
in the PoCT Trial. Of these, 58 met the selection criteria
and signed on to participate. Practices were then ran-
domised resulting in 26 practices in the control group and
32 practices in the intervention group. A total of 5234
patients (2034 in the control group and 3200 in the inter-
vention group) were recruited through these practices.
The clusters and participants progress throughout the Trial
is provided in a CONSORT diagram (Figure 1) [48].
Patient baseline characteristics
A baseline questionnaire was sent to patients following
consent and a response rate of 94.1% was achieved. Of the
4968 patients included in the analyses, 1967 had diabe-
tes, 3819 had hyperlipidaemia and 944 were on anticoag-
ulant therapy (patients could be registered in the Trial
with one or more conditions). The characteristics of these
patients were similar by treatment group and geographic
location. Overall the patients tended to be older (reflect-
ing the conditions of interest). The median age for
patients on anticoagulant therapy was slightly higher than
for the Trial participants overall, almost half of them
reported having multiple co-morbidities and a large pro-
portion were either overweight or obese. Patients with
diabetes were primarily diet and/or tablet controlled, had
been diagnosed for more than 5 years and a majority were
either overweight or obese. For those with hyperlipidae-
mia, over a third reported having heart disease, and over a
third indicated they had diabetes (see Additional file 2).
Discussion
The PoCT Trial is a complex study taking place in a GP set-
ting. The issues facing the implementation and design of
the Trial emphasise the difficulties of undertaking a RCT
in a GP setting and why RCTs in GP are often termed
'pragmatic' RCTs. As with the PoCT Trial, pragmatic RCTs
are suitable to evaluate effectiveness rather than to meas-
ure efficacy [49]. Such trials determine the benefit of a
treatment within routine clinical care rather than under
ideal conditions. Results reflect the variation that occurs
in the real world and are particularly suitable for interven-
tions that inform policy decisions.
A key methodological issue in pragmatic RCTs is balanc-
ing internal validity and external validity. This issue was
addressed for the PoCT Trial in the study design and eval-
uation protocol. External validity was maintained by min-
imising the exclusion criteria, allowing the GPs to
implement PoCT in their own manner within the practice
and allowing patients to choose not to have PoCT at any-
time during the Trial. Internal validity was maintained
through cluster randomisation of practices to reduce con-
tamination issues.
Evaluation protocol design
In developing the evaluation protocol and the data collec-
tion tools, three participant groups were considered – GPs
and their practices, patients and pathology providers. The
approach taken needed to balance data quality with the
pragmatic aspects necessary when undertaking a RCT in a
GP setting.
The PoCT Trial recruited a total of 58 practices located in
urban, rural and remote locations across three states in
Australia. The data required for the Trial needed to be col-
lected mainly by the practices themselves so the tools had
to be easy to use by GPs and device operators, not onerous
to complete and be integrated into the busy fee-for-service
structure of Australian GP. It was also necessary to allow
for variability between the practices in terms of their size,
location and capacity to participate in research and at the
same time ensure quality data were collected. The prac-
tices recruited ranged from large urban based multi gen-
eral practitioner practices with many practice nurses to
remote solo practices with one additional staff member.
The practices also varied in their capacity to undertake the
Trial tasks such as recruitment of patients (for example
understanding of consent, accuracy of practice databases)
and understanding the importance of quality data collec-
tion. Also the original and adapted Trial Design allowed
practices to implement the intervention in the ways that
suited their practices. As a result, practices could either
incorporate the PoCT devices into existing or new mini
clinics or, more commonly, as part of the consultation
process.Trials 2008, 9:50 http://www.trialsjournal.com/content/9/1/50
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CONSORT diagram showing flow of clusters and participants' progress through the Trial Figure 1
CONSORT diagram showing flow of clusters and participants' progress through the Trial.
Assessed for eligibility  (66 
practices)
Allocated to Intervention
  32 practices  (urban 8, rural 10, remote 14)
  3200 participants (subsequently found ineligible n=157)
Allocated to Control 
  26 practices (urban 9, rural 7, remote 10)
  2034 participants (subsequently found ineligible n=64)
Randomised (58 practices) 
Excluded: 
  Eligibility criteria not met (8 practices)
Withdrawn
Practices:
  6 practices withdrew (4 practices contributed data, 
  2 practices contributed no data)
Participants:
  Withdrew (313 participants and contributed data)
  Deceased (47 participants and contributed data)
Clusters:
Analysed
Practices:
  30 practices (urban 8, rural 10, remote 12)
Participants:
  3010 participants analysed
Excluded from analysis
  33 participants withdrew (contributed no data)
Withdrawn
Practices:
  3 practices withdrew (no data contributed)
Participants:
  Withdrew (57 participants and contributed data)
  Deceased (42 participants and contributed data)
Clusters:
Analysed
Practices:  
23 practices (urban 9, rural 6, remote 8)
Participants:
  1958 participants analysed
Excluded from analysis
  12 participants withdrew (contributed no data)Trials 2008, 9:50 http://www.trialsjournal.com/content/9/1/50
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The PoCT Trial included patients with one or more of
three conditions. This meant that any outcome measure
needed to be suitable for all these conditions, rather than
the most appropriate outcome for a particular condition.
For example, one of the most validated methods of deter-
mining good management of anticoagulant therapy is
measuring a patient's time in range. However, while this
is relevant for patients on warfarin therapy, it is not a suit-
able measure for diabetes or lipids management. Thus,
the percentage of patients and test results within target
range were selected as alternative measures of clinical
effectiveness as these were applicable for all three condi-
tions. Patients also formed the largest participant group in
the Trial; therefore data collection processes needed to be
manageable for more than 4500 patients. Taking into
account these issues, the approach taken by the PoCT Trial
to collect patient data was through a series of question-
naires. This was the most efficient method of data collec-
tion and the high response rate achieved for the baseline
patient questionnaire indicates that patients found this
approach acceptable. Similarly the list of SAEs reported
had to cover a broad range of possibilities, rather than be
condition specific.
At the pathology provider level, the practices participating
in the PoCT Trial utilised 23 different laboratories, repre-
senting 10 parent pathology companies, with each prac-
tice utilising on average 1.5 pathology laboratories.
Pathology results were required for several of the hypoth-
eses. Each pathology company used different testing rea-
gents and different electronic record systems and
considerable work was required to capture these data in a
format that could be used for the Trial.
The approach taken by the Trial Evaluation group was to
minimise the data collection undertaken by the GPs and
practices and where it was necessary for them to collect
data, incorporate this as much as possible into their every-
day practice. An example was the development of the
PoCT request/result form for the intervention practices.
This provided the practice with documentation of the test
request and result using the PoCT devices, but the dupli-
cate form was used by the Trial as a record of test results.
This form was also provided to the practices in an elec-
tronic format that could be included in their electronic
medical record systems.
Recruitment
The PoCT Trial retained 84.5% of practices and 86.1% of
patients. These high retention rates are likely to reflect the
interest by GPs and patients in PoCT and the effort made
by the researchers to minimise the impact on both the
practices and patients. Various support strategies known
to improve recruitment and compliance [50] were imple-
mented, including NSOs, a telephone support line and
regular newsletters, all of which may have contributed to
the continuation of practices in the Trial. At the same
time, the intervention practices reported that patients had
a high level of interest in PoCT. Through the use of the
data collection questionnaires, patients were contacted
regularly by the researchers during the Trial.
Limitations
Unfortunately, the PoCT Trial was not able to recruit suf-
ficient patients in two of the three conditions to obtain
desired power. The Trial Design required the recruitment
of practices in three geographic locations – urban, rural
and remote. However, the original Trial Design did not
consider the possibility that practices in rural or remote
locations would not have sufficient patient population to
meet the required sample size and hence the adapted Trial
Design allowed practices to be recruited knowing that
they could not meet the minimum requirement of
patients.
With any trial, ensuring adherence to the evaluation and
treatment protocol by participants is difficult, although
this is of less importance in a pragmatic RCT [49]. This dif-
ficulty was amplified for the PoCT Trial because of the
large number of participants and their geographic spread.
One of the aims of establishing NSOs in each region was
to provide a local link for practices and for the NSO to
monitor adherence to the protocol, which worked to
some extent. However, it was reliant on the relationship
between the NSO and the practices and the geographic
spread of practices meant that it was not possible for the
NSO to visit practices on a regular basis.
To maximise time the CNA of patient records was under-
taken for only a sample of patients. The descriptive analy-
sis suggests that the sample of patients was representative
of the entire patient population of the PoCT Trial in terms
of baseline characteristics and hence, results based on
analysis of CNA data are applicable to all Trial patients.
Conclusion
The PoCT Trial is one of the largest and most comprehen-
sive RCTs to evaluate the impact of PoCT in a GP setting.
There are few RCTs in this area and none have investigated
all the areas covered in this Trial or at the scale of this Trial
either in terms of the number of practices, the number of
patients or the number of pathology tests included
[8,18,27,28,51-53]. No previous trials and very few obser-
vational studies [16,17] have investigated the influence of
geographic location on PoCT. The results of the PoCT
Trial should provide a sound evidence base as to whether
PoCT (for the three conditions) should be implemented
by the government in Australian general practice.Trials 2008, 9:50 http://www.trialsjournal.com/content/9/1/50
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